Skip to main content

Allan Douglas Kirk, MD, PhD

David C. Sabiston, Jr. Distinguished Professor of Surgery
Chair, Department of Surgery
Professor of Surgery
Professor in Pediatrics
Professor in the Department of Immunology
Campus Mail: DUMC 3704, Durham, NC 27710

I am a surgeon with interest in immune management of transplant recipients. I am particularly interested in therapies that influence T cell costimulation pathways and adjuvant therapies that facilitate costimulation blockade to prevent the rejection of transplanted organs without undue suppression of protective immunity. I am also interested in understanding how injury, such as that occurring during trauma or in elective surgery, influences immune responses and subsequent healing following injury.

Costimulation Blockade in Organ Transplantion

Allan D. Kirk, MD, PhD, Department of Surgery Chairman
David C. Sabiston, Jr. Professor of Surgery

Education and Training

  • Fellow, Multi Organ Transplantation, University of Wisconsin at Madison, 1995 - 1997
  • Chief Resident, Surgery, Duke University, 1994 - 1995
  • Senior Resident, Surgery, Duke University, 1992 - 1994
  • Research Fellow, Surgery, Duke University, 1989 - 1992
  • Intern & Junior Resident, Surgery, Duke University, 1987 - 1989
  • Ph.D., Duke University, 1992
  • M.D., Duke University School of Medicine, 1987
  • B.S., Old Dominion University, 1983

Selected Grants

Publications

Hoffmann, S. C., E. M. Stanley, E. D. Cox, N. Craighead, S. P. Perfetto, D. M. Harlan, A. D. Kirk, and P. J. Blair. “The polymorphism at-330 in the interleukin-2 gene results in a significant increase in IL-2 protein following co-stimulation of peripheral blood lymphocytes with anti-CD3/CD28.” In Faseb Journal, 15:A1055–A1055. FEDERATION AMER SOC EXP BIOL, 2001.

Scholars@Duke

Hoffmann, S. C., E. M. Stanley, E. D. Cox, B. S. DiMercurio, D. E. Koziol, D. M. Harlan, A. D. Kirk, and P. J. Blair. “Correlation of cytokine gene polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28 stimulated peripheral blood lymphocytes.” In Faseb Journal, 15:A666–A666. FEDERATION AMER SOC EXP BIOL, 2001.

Scholars@Duke

Abbott, K. C., J. D. Oliver, I. Hypolite, L. L. Lepler, A. D. Kirk, C. W. Ko, C. A. Hawkes, C. A. Jones, and L. Y. Agodoa. “Hospitalizations for bacterial septicemia after renal transplantation in the united states.” Am J Nephrol 21, no. 2 (March 2001): 120–27. https://doi.org/10.1159/000046234.

Full Text

Xu, H., E. Elster, D. Batty, J. Berning, L. Burkly, R. Kampen, S. Swanson, D. Tadaki, D. Harlan, and A. Kirk. “Effects of dose and duration of anti-CD154 antibody therapy in preventing renal allograft rejection in a nonhuman primate model.” Transplant Proc 33, no. 1–2 (February 2001): 223–24. https://doi.org/10.1016/s0041-1345(00)01983-7.

Full Text

Abbott, K. C., E. S. Sawyers, J. D. Oliver, C. W. Ko, A. D. Kirk, P. G. Welch, T. G. Peters, and L. Y. Agodoa. “Graft loss due to recurrent focal segmental glomerulosclerosis in renal transplant recipients in the United States.” Am J Kidney Dis 37, no. 2 (February 2001): 366–73. https://doi.org/10.1053/ajkd.2001.21311.

Full Text

Elster, E. A., H. Xu, D. K. Tadaki, L. C. Burkly, J. D. Berning, R. E. Baumgartner, F. Cruzata, N. B. Patterson, D. M. Harlan, and A. D. Kirk. “Primate skin allotransplantation with anti-CD154 monotherapy.” Transplant Proc 33, no. 1–2 (February 2001): 675–76. https://doi.org/10.1016/s0041-1345(00)02197-7.

Full Text

Irwin, Garth, and Alexander D. Kirk. “Intermediates in chromium(III) photochemistry.” Coordination Chemistry Reviews 211, no. 1 (January 2001): 25–43. https://doi.org/10.1016/s0010-8545(00)00281-2.

Full Text

Leitman, S. F., A. D. Kirk, D. S. Gladden, and J. Kopp. “Plasma exchange in the treatment of recurrent focal segmental glomerulosclerosis (FSGS) following renal transplant.” In Transfusion, 40:54S-55S. AMER ASSOC BLOOD BANKS, 2000.

Scholars@Duke

Tadaki, D. K., N. Craighead, A. Saini, A. Celniker, L. C. Burkly, K. P. Lee, J. P. Chute, D. M. Harlan, and A. D. Kirk. “Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity.” Transplantation 70, no. 1 (July 15, 2000): 162–67.

Scholars@Duke

Pages